Tag: biotechnology
-
Celgene, MorphoSys Partner on Multiple Myeloma Antibody
Celgene Corporation, a biopharmaceutical company in Summit, New Jersey, agreed to license technology and invest in the biotechnology company MorphoSys AG in Munich, Germany for commercializing a monoclonal antibody developed by MorphoSys to treat multiple myeloma and some forms of leukemia. The total potential value of the deal, if all contingencies are met, is €628…
-
AstraZeneca, Roche to Share Preclinical Research Data
The global pharmaceutical companies AstraZeneca and Roche agreed to share early-stage drug research data to speed product development and identify candidates with a greater chance of success. Financial aspects of the collaboration were not disclosed. The two companies will furnish their research data on investigational compounds to a third party, MedChemica, a computational chemistry service…
-
Light-Enabled Nanoparticles Detect Early Infection Signs
Biomedical and genomic researchers at Duke University in North Carolina developed a technique with light and silver nanoparticles to detect infections earlier than when patients may even report symptoms. The team led by biomedical engineering professor Tuan Vo-Dinh and genomic medicine professor Geoffrey Ginsburg published its findings online in a recent issue of the journal…
-
Biotech Developing Genetics Therapies Gains $101M in IPO
The biotechnology company bluebird bio in Cambridge, Massachusetts developing therapies for genetic disorders raised $101 million through its initial public offering (IPO) of 5.9 million shares priced at $17.00 a share. The company’s stock, trading on the NASDAQ under the code BLUE was priced at $26.00 a share at 11:00 am ET today. bluebird bio…
-
Stem Cells Generate High-Quality Liver Cells for Drug Tests
Medical researchers at University of Edinburgh in Scotland created a process for inducing pluripotent stem cells to transform into liver cells with the same consistency and quality needed to test drugs for toxicity. A spin-off company from the university has also formed to take the research to market. The team led by Edinburgh’s David Hay…
-
Science Business Content Partner: The Life Sciences Report
Science Business is pleased to offer a new feature, the latest entries from the investment newsletter, The Life Sciences Report, published by Streetwise Reports. The Life Sciences Report features interviews with investment experts in biotechnology, pharmaceuticals, medical devices, and diagnostics. Science Business aims to provide breaking news developments in the science and business of the…
-
AstraZeneca Acquires Respiratory Disease Therapy Developer
The global pharmaceutical company AstraZeneca is buying Pearl Therapeutics in Redwood City, California, a developer of treatments for chronic respiratory diseases. The deal is valued initially at $560 million, but has a total potential value of $1.15 billion, adding in subsequent milestone and royalty payments. The seven year-old Pearl Therapeutics develops small-molecule treatments for chronic…
-
University, Biotech, Life Technologies Partner on Gene Tests
University at Buffalo in New York, the biotechnology company Empire Genomics, and genetics systems developer Life Technologies are establishing facilities at the university to conduct genomic sequencing for research and diagnostics to support personalized medicine. Financial terms of the partnership were not disclosed. Under the deal, Life Technologies is providing equipment from its Ion line…
-
GSK Licenses Biotech Antibody for Arthritis, MS Drugs
The biotechology company MorphoSys AG in Germany says the pharmaceutical company GlaxoSmithKline is licensing its targeted human antibody drug candidate MOR103 to treat rheumatoid arthritis. The deal has a potential value to MorphoSys of €445.5 million ($US 579 million), not counting future sales royalties. MorphoSys develops engineered antibodies for therapies and diagnostics. One of its…
-
Stem Cell Process Makes Red Blood, Platelets in Quantities
Medical and public health researchers at Boston University developed a lab process for generating from adult stem cells, unlimited quantities of red blood and platelet cells, the type of cells in donated blood. The team led by George Murphy, co-director of the university’s Center for Regenerative Medicine, published its findings online yesterday in the journal Blood…